Benchmark provided earnings guidance for the fiscal year 2023. Whilst this will take the company's profit expectations down in half for next year to limited growth expected in adjusted EBITDA in financial year 2023, this is due to the lead time and moving capacity across to the new model. It will also fundamentally reduce the financial risk around loan utilization, which exists in the current PSV model, whilst strengthening the company's position in the medium term by allowing the company to better serve the customers.

Overall, for the group, even with reduced profit expectations in Health for next year, The company expects to still deliver good growth in line with previous medium-term guidance.